Drug delivery Systems (DDSs) are polymeric or lipid carrier systems that transport medications to their targets or receptor sites in a way that ensures their maximum Therapeutic Activity, prevents drug degradation or inactivation while travelling to the target site (s), and shields the body from negative effects caused by inadvertent administration. It can be characterised as a formulation or a tool that permits the entrance of a medicinal material into the body and increases its efficacy and safety by regulating the rate, timing, and site of drug release.
Release of the drug(s) with the highest levels of safety, effectiveness, and dependability is the aim of an ideal DDS. Combining a number of cutting-edge methods, the Novel Drug Delivery System (NDDS), also known as controlled DDS In order to improve medication potency, control drug release, increase safety, and specifically target a drug to a targeted region, novel drug delivery systems (NDDS), also known as Controlled DDS, combine cutting-edge technology and innovative dosage forms. The definition of "controlled release" extends beyond actions that solely include continuous release. In other words, the release kinetics of controlled release must be able to be predicted and replicated.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia